Status: Recruiting
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Participants needed: 60
Trial details
Phase: Phase 4Age: 1-17Biological sex: AllType: InterventionalSponsor: Children's Mercy Hospital Kansas CityUpdated: Sep 26, 2025Locations: 1
Eligibility criteria
Received a heart transplant [+6]
History of repeated infections necessitating adjustment in immunosuppression to... [+1]